Loading stock data…
SYRE
$76.43+1.39 (+1.85%)
Market ClosedLast close May 11
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $76.43. The stock is currently near its 52-week high of $78.80, remaining 132.2% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why SYRE maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$76.43
Potential Upside
5%
Whystock Fair Value$80.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$94.13+23.2%
Range$78.00 – $115.00
Fundamentals
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.92%
Volume
Today's trading volume
1.33M
Recent News
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive […]
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise
Spyre Therapeutics recently reported positive Phase 2 SKYLINE trial results for its SPY001 antibody in moderate-to-severe ulcerative colitis, and in mid-April closed an underwritten public offering that raised about US$463.5 million in gross proceeds. The combination of encouraging efficacy and dosing data for SPY001 with a sizeable capital raise gives Spyre more resources to advance long-acting and combination antibody therapies for inflammatory bowel disease and rheumatic...
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final total reflects the full exercise of the underwriters’ option to purchase an additional 975,000 shares, bringing the total number of […]
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Spyre Therapeutics, Inc. (NASDAQ:SYRE) ranks 4th on this list. Following a string of clinical successes in early April, Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock has become a favorite for managers looking to capitalize on the multi-billion dollar Inflammatory Bowel Disease market. […]
Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics Inc (NASDAQ:SYRE) is among the best 52-week high US stocks to buy. On April 16, Spyre Therapeutics Inc (NASDAQ:SYRE) said in a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the […]